Too many middlemen disconnects you from patients.

See How Close
Lost in Transition Telephones
Lost in Transition

Treating rare disease shouldn’t be like a bad game of telephone, with each step generating chaos and confusion. Patient adherence suffers, quality of care diminishes, manufacturers miss out on vital feedback and cost goes up. But imagine if you could cut past all that. We did.

Learn More

News Details

October 06, 2017

Dohmen sponsors NORD Rare Summit, October 16-17

The Dohmen Life Science Services (DLSS) team will join hundreds of rare disease patients, drug developers and experts from the FDA and NIH at the National Organization for Rare Disorders (NORD) Summit, Oct. 16-17, in Washington, D.C. The event is expected to attract more than 500 people interested in the latest developments in orphan drug innovation and patient care.

“Just steps away from the Capital, the rare disease community will converge at NORD to discuss the latest breakthroughs in drug research, development and patient support,” said Lynda Parker, Chief Business Development Officer, DLSS. “NORD is an important forum for critical conversations impacting the rare disease community and we are very proud to continually sponsor it.”

The DLSS team will share an integrated wrap-around patient-service model focused on reducing the burden of disease and increasing therapy adherence through coordinated care, patient education, and comprehensive support.

The two-day summit will feature more than 80 speakers, breakout tracks, groundbreaking keynotes and meaningful patient participation. For more information and to access the event’s agenda, visit NORD Rare Summit.